RDHL News and Press, Redhill Biopharma Ltd.

Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...

Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...

RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040 PR Newswire New Chinese patent notice of allowance issued covering opaganib in combination with immune checkpoint inhibitors (ICIs) as a method of inducing an ...

RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035 PR Newswire The new Chinese patent for opaganib as a therapy for inhibition of single-stranded RNA virus replication (notably Ebola Disease Virus) is valid through 2035 and adds to opaganib's ...

RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study PR Newswire First patient enrolled in the global, 300-patient, Phase 2 adaptive platform trial arm of RHB-107 (upamostat) 1 for early COVID-19 outpatient treatment, funded through non-...

2024-04-08 14:07:22 ET More on RedHill RedHill Biopharma looks to raise $1.25M in a direct offering of securities RedHill gains after new patent grant for Talicia for H. pylori treatment through 2042 Financial information for RedHill Read the full article o...

RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights PR Newswire RedHill continues corporate transformation to focus on U.S. government-funded pipeline development in underserved, sizeable therapeutic areas with a disciplined cost-base ...

2024-04-02 07:32:23 ET More on RedHill RedHill gains after new patent grant for Talicia for H. pylori treatment through 2042 Financial information for RedHill Read the full article on Seeking Alpha For further details see: RedHill Biopharma looks to raise...

RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price PR Newswire TEL AVIV, Israel and RALEIGH, N.C. , April 2, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialt...

RedHill Announces New USPTO Patent Covering Talicia® Through 2034 PR Newswire U.S. Patent and Trademark Office (USPTO) issues new patent covering Talicia 1 as an all-in-one treatment of Helicobacter pylori (H. pylori), supporting Talicia protection until Feb...